A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis

The goal of this study is to find out if a medication called upadacitinib can help treat a condition called Eosinophilic Esophagitis (EoE). The main question it aims to answer are: \- Does upadacitinib in addition to topical corticosteroids help reduce EoE disease activity? Participants will: * Take upadacitinib or placebo every day for 12 weeks, followed by 12 weeks of upadacitinib * Fill out surveys and answer health questions * Visit the clinic every 4 weeks for checkups and tests

NCT Number	NCT07588568
Lead Sponsor	University of North Carolina, Chapel Hill Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), AbbVie
Conditions	EoE, Eosinophilic Esophagitis, Eosinophilic Esophagitis (EoE)
Enrollment	52 participants
Start Date	2026-07
Primary Completion	2030-02 (estimated)
Study Completion	2030-06 (estimated)
Updated on ClinicalTrials.gov	2026-05-15